Correlation between coagulation profile findings and bleeding complications after ultrasound-guided biopsies: 434 cases (1993-1996)

Medical records of 434 consecutive dogs (n=310) and cats (n=124) that received coagulation studies prior to ultrasound-guided biopsy procedures between January 1993 and June 1996 were reviewed for bleeding complications. Minor complications occurred in 21.9% of cases. Major complications occurred in 6% of the cases. Significant bleeding complications were observed in thrombocytopenic cases (P=0.0001). Dogs with a prolonged one-stage prothrombin time (OSPT) (P=0.031) and cats with prolonged activated partial thromboplastin time (aPTT) (P=0.024) were more likely to have complications than patients with normal values. Adequate tissue for histopathological diagnosis was obtained in 96.3% of cases. The likelihood of complication was smaller when the liver was biopsied than when the kidney was biopsied (n=259; P=0.0327). Ultrasound-guided biopsy of intracavitary structures is an effective and relatively safe procedure, but delay of the procedure should be considered when thrombocytopenia is present in the patient.

Download Full-text

Re: Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications

Clinical Radiology ◽

10.1016/j.crad.2008.06.013 ◽

2008 ◽

Vol 63 (12) ◽

pp. 1386-1387 ◽

Cited By ~ 1

Author(s):

G. Giannarini ◽

A. Mogorovich ◽

C. Selli

Keyword(s):

Transrectal Ultrasound ◽

Bleeding Complications ◽

Minor Bleeding ◽

Ultrasound Guided ◽

Guided Biopsy ◽

Ultrasound Guided Biopsy

Download Full-text

Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications

Clinical Radiology ◽

10.1016/j.crad.2007.09.014 ◽

2008 ◽

Vol 63 (5) ◽

pp. 557-561 ◽

Cited By ~ 39

Author(s):

O.T. Halliwell ◽

G. Yadegafar ◽

C. Lane ◽

K.C. Dewbury

Keyword(s):

Transrectal Ultrasound ◽

Bleeding Complications ◽

Minor Bleeding ◽

Ultrasound Guided ◽

Guided Biopsy ◽

Ultrasound Guided Biopsy

Download Full-text

BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol

International Journal of Gynecological Cancer ◽

10.1136/ijgc-2021-002995 ◽

2021 ◽

pp. ijgc-2021-002995

Author(s):

Stamatios Petousis ◽

Sabrina Croce ◽

Michel Kind ◽

Chrysoula Margioula-Siarkou ◽

Guillame Babin ◽

...

Keyword(s):

Sample Size ◽

Transvaginal Ultrasound ◽

Pathological Diagnosis ◽

Diagnostic Tools ◽

Histopathological Diagnosis ◽

Ultrasound Guided ◽

Pelvic Magnetic Resonance Imaging ◽

Vaginal Ultrasound ◽

Guided Biopsy ◽

Ultrasound Guided Biopsy

BackgroundThe pre-operative differential diagnosis between a uterine leiomyoma and a sarcoma can be a challenge. Available diagnostic tools have difficulty distinguishing between the two pathologies.Primary ObjectiveΤo evaluate the possibility of a pre-operative pathological diagnosis of atypical uterine muscle tumors by vaginal ultrasound-guided biopsy (VUGB).Study HypothesisDiagnostic performance of ultrasound-guided biopsy will be capable of differentiating a leiomyoma from a sarcoma with a sensitivity of >90%.Trial DesignA prospective multi-center interventional study will be performed at 10 tertiary French centers. Vaginal ultrasound Doppler examination and pelvic magnetic resonance imaging will be performed before surgery. VUGB will then be performed by a specialist radiologist. The biopsy will be obtained by performing transvaginal ultrasound under local anesthesia with lidocaine using a 16G needle. At least 4–5 specimens will be obtained in order to provide a histopathological diagnosis. All patients included in the study will be operated by laparotomy. All patients included in the study will be followed up for the subsequent 3 years according to their pathological results.Major Inclusion/Exclusion CriteriaAll patients >35 years old diagnosed with a suspicious uterine tumor will be included.Primary EndpointSensitivity of VUGB on pathological diagnosis.Sample SizeConsidering a sensitivity of 90% (H0) as acceptable and a sensitivity of 95% (H1) as excellent, a sample size of 250 evaluable patients will be necessary to achieve 80% statistical power with a 5% type 1 statistical error.Estimated Dates for Completing Accrual and Presenting ResultsAccrual will be completed in December 2024 with results presented in December 2029.Trial RegistrationInstitutional Review Board (Ethic Committee of Paris Ile de France 6) no 2018-A02343-52.

Download Full-text